GLP-1 drugs halve all-cause death but slightly increase acute pancreatitis risk in 1.5 million users | Research

The takeaway

In 1.56 million GLP-1 users vs 18.65 million non-users from TriNetX, GLP-1 drugs reduced all-cause death 45% (HR 0.554) but slightly increased acute pancreatitis risk 6% (HR 1.058), primarily in the first 6 months, with no increased chronic pancreatitis or pancreatic cancer.

45% lower death risk
The largest GLP-1 safety study ever (20 million patients) shows 45% mortality reduction with a small, manageable 6% acute pancreatitis increase in the first 6 months

What the researchers found

All-cause death: HR 0.554 (0.542-0.566). Composite pancreatitis: HR 1.062 (1.023-1.102). Acute pancreatitis: HR 1.058 (1.015-1.103), mainly first 6 months. Chronic pancreatitis: NS. Pancreatic cancer: NS. <65: greater mortality benefit. 1.56M GLP-1 users vs 18.65M non-users.

Why it matters

This is the largest GLP-1 safety/benefit analysis ever conducted. The 45% mortality reduction is extraordinary, while the 6% pancreatitis increase is manageable—clearly favorable benefit-risk ratio.

How the study worked

Retrospective TriNetX federated network study (2018-2024). 1:1 propensity score matching. Cox regression. Sensitivity analyses (early vs late). Subgroup analyses (age, sex, comorbidities).

What this study cannot tell us

Observational (healthy user bias possible). Propensity matching cannot fully eliminate confounding. GLP-1 users inherently differ from non-users. TriNetX data quality varies.

How to read the evidence

Massive observational study from federated network. Extraordinary scale but observational limitations.

When this study was published

Published in 2025; data 2018-2024.

The bigger picture

A 45% mortality reduction is among the largest ever reported for any drug class. The small acute pancreatitis risk, concentrated in early treatment, is a manageable trade-off for this extraordinary survival benefit.

Questions still open

Is the 45% mortality reduction real or inflated by healthy user bias?
Should patients be monitored for pancreatitis in the first 6 months?
Does the mortality benefit apply to non-diabetic, non-obese populations?

Common questions

Do GLP-1 drugs save lives?

This study of over 20 million patients found GLP-1 drug users had 45% lower risk of death from any cause—the largest mortality reduction ever reported for these drugs. The benefit was even greater in patients under 65 and those with heart disease or kidney disease.

Do GLP-1 drugs cause pancreatitis?

There is a small increase in acute pancreatitis risk (6%), mostly in the first 6 months of treatment. However, there was no increase in chronic pancreatitis or pancreatic cancer. The 45% mortality reduction far outweighs this small, manageable risk. Report severe abdominal pain to your doctor promptly.

Read the original research

Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.

Cardiovascular diabetology, 24(1), 438

View on PubMed ↗Publisher’s paper ↗

Citation

Tartaglia, Enrico; Bucci, Tommaso; Rossi, Michele; Rigutini, Andrea Galeazzo; Askarinejad, Amir; Alam, Uazman; Nabrdalik, Katarzyna; Boriani, Giuseppe; Lip, Gregory Y H. (2025). Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.. Cardiovascular diabetology, 24(1), 438. https://doi.org/10.1186/s12933-025-02986-0